Rankings / Mood, Anxiety & Stress

Zuranolone (Zurzuvae)

Mood, Anxiety & Stress · GABA-A neurosteroid (positive allosteric modulator)

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

gabacontrolled-substanceprescription
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Zuranolone (Zurzuvae) as B (6.8/10) based on strong evidence, high in ppd benefit magnitude, and a med-risk safety profile.

Sage Therapeutics/Biogen.

Studied, labeled, or reported-use context: 50 mg PO once daily x 14 days (with fat-containing meal) — Rx; not individualized guidance.

What the evidence says

Sage Therapeutics/Biogen. First oral postpartum depression treatment (vs IV brexanolone/Zulresso 2019). 14-day course produces rapid sustained improvement. FDA declined MDD indication after Phase 3 SKYLARK and SHORELINE didn't replicate strong PPD effect — class-wide debate about whether neurosteroids are MDD-suitable. Schedule IV controlled.

Mechanism

Synthetic neurosteroid analog of allopregnanolone; positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors; rapid normalization of GABAergic tone disrupted in postpartum depression

Studied, labeled, or reported dose & route

50 mg PO once daily x 14 days (with fat-containing meal)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Zuranolone (Zurzuvae)'s effects?
Read Off Label rates the evidence for Zuranolone (Zurzuvae) as Strong and the benefit magnitude as high in ppd, producing an overall grade of B (6.8/10). Sage Therapeutics/Biogen.
What safety findings are reported for Zuranolone (Zurzuvae)?
Zuranolone (Zurzuvae) has a med risk profile in the database. Med (somnolence, dizziness, sedation — driving warning, full label Schedule IV; fetal harm — contraception required for 1 wk after; not curative, courses are 14 days) Legal status: Rx (Schedule IV; FDA-approved PPD only).
What doses or routes are reported for Zuranolone (Zurzuvae)?
50 mg PO once daily x 14 days (with fat-containing meal) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Zuranolone (Zurzuvae) work?
Synthetic neurosteroid analog of allopregnanolone; positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors; rapid normalization of GABAergic tone disrupted in postpartum depression

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.